384802741	384802741	CD	B-NP	O
|	|	NN	I-NP	O
NMC	NMC	NN	I-NP	O
|	|	NN	I-NP	O
12855272	12855272	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
3948854	3948854	CD	B-NP	O
|	|	CC	I-NP	O
3/1/2004	3/1/2004	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	B-protein
PNEUMONIA	PNEUMONIA	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Signed	Signed	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
DIS	DIS	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
3/1/2004	3/1/2004	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Signed	Signed	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
8/29/2005	8/29/2005	CD	B-NP	O
ATTENDING	ATTENDING	NN	I-NP	O
:	:	:	O	O
PALMER	PALMER	NNP	B-NP	O
JEANGILLES	JEANGILLES	NNP	I-NP	O
MD	MD	NNP	I-NP	O
SERVICE	SERVICE	NNP	I-NP	O
:	:	:	O	O
General	General	NNP	B-NP	O
Medical	Medical	NNP	I-NP	O
Service	Service	NNP	I-NP	O
Arb	Arb	NNP	I-NP	O
Gard	Gard	NNP	I-NP	O
Sa	Sa	NNP	I-NP	O
ADMISSION	ADMISSION	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
:	:	:	O	O
Pneumonia	Pneumonia	NNP	B-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
:	:	:	O	O
Pneumonia	Pneumonia	NN	B-NP	O
associated	associate	VBN	B-VP	O
with	with	IN	B-PP	O
PICC	PICC	NN	B-NP	O
line	line	NN	I-NP	O
bacteremia	bacteremia	NN	I-NP	O
.	.	.	O	O

CHIEF	CHIEF	NN	B-NP	B-protein
COMPLAINT	COMPLAINT	NN	I-NP	O
:	:	:	O	O
Diaphoresis	Diaphoresis	NN	B-NP	O
and	and	CC	I-NP	O
shortness	shortness	NN	I-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
.	.	.	O	O

HISTORY	HISTORY	NN	B-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	JJ	B-NP	O
ILLNESS	ILLNESS	NN	I-NP	O
:	:	:	O	O
Mr.	Mr.	NNP	B-NP	O
Garrigan	Garrigan	NNP	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
68-year-old	68-year-old	JJ	I-NP	O
gentleman	gentleman	NN	I-NP	O
with	with	IN	B-PP	O
known	known	JJ	B-NP	O
coronary	coronary	JJ	I-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
status	status	NN	I-NP	O
post	post	IN	B-PP	O
2-vessel	2-vessel	JJ	B-NP	O
coronary	coronary	JJ	I-NP	O
artery	artery	NN	I-NP	O
bypass	bypass	IN	B-PP	O
grafting	graft	VBG	B-VP	O
in	in	IN	B-PP	O
5/4	5/4	CD	B-NP	O
,	,	,	O	O
hypertension	hypertension	NN	B-NP	O
,	,	,	O	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
status	status	NN	I-NP	O
post	post	NN	I-NP	O
cardioversion	cardioversion	NN	I-NP	O
on	on	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
,	,	,	O	O
hypercholesterolemia	hypercholesterolemia	NN	B-NP	O
,	,	,	O	O
aortic	aortic	JJ	B-NP	O
stenosis	stenosis	NN	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
aortic	aortic	JJ	I-NP	O
valve	valve	NN	I-NP	O
replacement	replacement	NN	I-NP	O
with	with	IN	B-PP	O
bioprosthetic	bioprosthetic	JJ	B-NP	O
valve	valve	NN	I-NP	O
,	,	,	O	O
diabetes	diabetes	NN	B-NP	O
mellitus	mellitus	NN	I-NP	O
,	,	,	O	O
cervical	cervical	JJ	B-NP	O
stenosis	stenosis	NN	I-NP	O
,	,	,	O	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
a	a	DT	B-NP	O
recent	recent	JJ	I-NP	O
admission	admission	NN	I-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
Land	Land	NNP	I-NP	O
As	As	IN	B-PP	O
Rohay	Rohay	NNP	B-NP	O
Hospital	Hospital	NNP	I-NP	O
for	for	IN	B-PP	O
bilateral	bilateral	JJ	B-NP	O
brachial	brachial	JJ	I-NP	O
plexopathy	plexopathy	NN	I-NP	O
of	of	IN	B-PP	O
unknown	unknown	JJ	B-NP	O
etiology	etiology	NN	I-NP	O
,	,	,	O	O
who	who	WP	B-NP	O
is	be	VBZ	B-VP	O
receiving	receive	VBG	I-VP	O
three	three	CD	B-NP	O
weeks	week	NNS	I-NP	O
of	of	IN	B-PP	O
intravenous	intravenous	JJ	B-NP	O
cefotaxime	cefotaxime	NN	I-NP	O
as	as	IN	B-PP	O
empiric	empiric	JJ	B-NP	O
Lyme	Lyme	NN	I-NP	O
treatment	treatment	NN	I-NP	O
as	as	IN	B-PP	O
a	a	DT	B-NP	O
possible	possible	JJ	I-NP	O
cause	cause	NN	I-NP	O
for	for	IN	B-PP	O
his	his	PRP$	B-NP	O
plexopathy	plexopathy	NN	I-NP	O
,	,	,	O	O
who	who	WP	B-NP	O
presents	present	VBZ	B-VP	O
with	with	IN	B-PP	O
shortness	shortness	NN	B-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
.	.	.	O	O

While	While	IN	B-SBAR	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
Sieu	Sieu	NNP	I-NP	O
Iebri	Iebri	NNP	I-NP	O
General	General	NNP	I-NP	O
Hospital	Hospital	NNP	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
developed	develop	VBD	B-VP	O
shortness	shortness	NN	B-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
one-and-a-half	one-and-a-half	NN	I-NP	O
day	day	NN	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
was	be	VBD	B-VP	O
associated	associate	VBN	I-VP	O
with	with	IN	B-PP	O
significant	significant	JJ	B-NP	O
diaphoresis	diaphoresis	NN	I-NP	O
and	and	CC	I-NP	O
fevers	fever	NNS	I-NP	O
intermittently	intermittently	RB	B-ADVP	O
for	for	IN	B-PP	O
four	four	CD	B-NP	O
days	day	NNS	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

Of	Of	IN	B-PP	O
note	note	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
denied	deny	VBD	B-VP	O
any	any	DT	B-NP	O
dysuria	dysuria	NN	I-NP	O
,	,	,	O	O
cough	cough	NN	B-NP	O
,	,	,	O	O
sinus	sinus	NN	B-NP	O
pain	pain	NN	I-NP	O
,	,	,	O	O
diarrhea	diarrhea	NN	B-NP	O
,	,	,	O	O
ear	ear	JJ	B-NP	O
pain	pain	NN	I-NP	O
,	,	,	O	O
pleuritic	pleuritic	JJ	B-NP	B-protein
chest	chest	NN	I-NP	I-protein
pain	pain	NN	I-NP	I-protein
,	,	,	O	O
calf	calf	NN	B-NP	O
pain	pain	NN	I-NP	O
,	,	,	O	O
paroxysmal	paroxysmal	JJ	B-NP	O
nocturnal	nocturnal	JJ	I-NP	O
dyspnea	dyspnea	NN	I-NP	O
,	,	,	O	O
or	or	CC	O	O
orthopnea	orthopnea	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
taken	take	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
emergency	emergency	NN	I-NP	O
department	department	NN	I-NP	O
where	where	WRB	B-ADVP	O
a	a	DT	B-NP	O
chest	chest	NN	I-NP	O
x-ray	x-ray	NN	I-NP	O
demonstrated	demonstrate	VBD	B-VP	O
a	a	DT	B-NP	O
new	new	JJ	I-NP	O
right	right	JJ	I-NP	O
upper	upper	JJ	I-NP	O
lobe	lobe	NN	I-NP	O
pneumonia	pneumonia	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
emergency	emergency	NN	I-NP	O
department	department	NN	I-NP	O
and	and	CC	O	O
admitted	admit	VBN	B-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
inpatient	inpatient	NN	I-NP	O
medical	medical	JJ	I-NP	O
service	service	NN	I-NP	O
.	.	.	O	O

PAST	PAST	NNP	B-NP	O
MEDICAL	MEDICAL	NNP	I-NP	O
HISTORY	HISTORY	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

Coronary	Coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
status	status	NN	I-NP	O
post	post	IN	B-PP	O
2-vessel	2-vessel	JJ	B-NP	O
coronary	coronary	JJ	I-NP	O
artery	artery	NN	I-NP	O
bypass	bypass	IN	B-PP	O
grafting	graft	VBG	B-VP	O
in	in	IN	B-PP	O
4/5	4/5	CD	B-NP	O
2	2	CD	I-NP	O
.	.	.	O	O

Hypertension	Hypertension	NN	B-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Atrial	Atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
status	status	NN	I-NP	O
post	post	NN	I-NP	O
cardioversion	cardioversion	NN	I-NP	O
on	on	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Hypercholesterolemia	Hypercholesterolemia	NN	B-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Aortic	Aortic	JJ	B-NP	O
stenosis	stenosis	NN	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	B-protein
post	post	NN	I-NP	I-protein
aortic	aortic	JJ	I-NP	I-protein
valve	valve	NN	I-NP	I-protein
replacement	replacement	NN	I-NP	I-protein
-LRB-	-LRB-	NN	I-NP	I-protein
bioprosthesis	bioprosthesis	NN	I-NP	I-protein
-RRB-	-RRB-	NN	I-NP	I-protein
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Diabetes	Diabetes	NN	B-NP	O
mellitus	mellitus	NN	I-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Bilateral	Bilateral	JJ	B-NP	O
brachial	brachial	JJ	I-NP	O
plexopathy	plexopathy	NN	I-NP	O
of	of	IN	B-PP	O
unknown	unknown	JJ	B-NP	O
etiology	etiology	NN	I-NP	O
,	,	,	O	O
but	but	CC	O	O
attributed	attribute	VBN	B-VP	O
to	to	TO	B-PP	O
Lyme	Lyme	NN	B-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
being	be	VBG	I-VP	O
treated	treat	VBN	I-VP	O
four	four	CD	B-NP	O
with	with	IN	B-PP	O
three	three	CD	B-NP	O
weeks	week	NNS	I-NP	O
of	of	IN	B-PP	O
IV	IV	CD	B-NP	O
cefotaxime	cefotaxime	NN	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
brachial	brachial	JJ	I-NP	O
plexopathy	plexopathy	NN	I-NP	O
had	have	VBD	B-VP	O
improved	improve	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
point	point	NN	I-NP	O
where	where	WRB	B-ADVP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
able	able	JJ	B-ADJP	O
to	to	TO	B-VP	O
lift	lift	VB	I-VP	O
his	his	PRP$	B-NP	O
arms	arm	NNS	I-NP	O
and	and	CC	O	O
do	do	VB	B-VP	O
his	his	PRP$	B-NP	O
own	own	JJ	I-NP	O
ADLs	ADL	NNS	I-NP	O
.	.	.	O	O

When	When	WRB	B-ADVP	O
he	he	PRP	B-NP	O
first	first	RB	B-ADVP	O
presented	present	VBD	B-VP	O
with	with	IN	B-PP	O
this	this	DT	B-NP	O
condition	condition	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
near	near	JJ	I-NP	O
complete	complete	JJ	I-NP	O
paralysis	paralysis	NN	I-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
motor	motor	NN	I-NP	O
function	function	NN	I-NP	O
in	in	IN	B-PP	O
his	his	PRP$	B-NP	O
upper	upper	JJ	I-NP	O
extremities	extremity	NNS	I-NP	O
without	without	IN	B-PP	O
loss	loss	NN	B-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
sensory	sensory	JJ	I-NP	O
function	function	NN	I-NP	O
,	,	,	O	O
per	per	IN	B-PP	O
report	report	NN	B-NP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Cervical	Cervical	JJ	B-NP	O
stenosis	stenosis	NN	I-NP	O
and	and	CC	O	O
foraminal	foraminal	JJ	B-NP	O
stenosis	stenosis	NN	I-NP	O
,	,	,	O	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
congestive	congestive	JJ	B-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
with	with	IN	B-PP	O
an	an	DT	B-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
of	of	IN	B-PP	O
45	45	CD	B-NP	O
%	%	NN	I-NP	O
.	.	.	O	O

ALLERGIES	ALLERGIES	NNS	B-NP	O
:	:	:	O	O
No	No	DT	B-NP	O
known	know	VBN	I-NP	O
drug	drug	NN	I-NP	O
allergies	allergy	NNS	I-NP	O
.	.	.	O	O

MEDICATIONS	MEDICATIONS	NNS	B-NP	O
:	:	:	O	O
Metformin	Metformin	NN	B-NP	O
1000	1000	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.a.m.	q.a.m.	NN	I-NP	O
and	and	CC	O	O
500	500	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.p.m.	q.p.m.	NN	I-NP	O
,	,	,	O	O
simvastatin	simvastatin	NN	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.	q.	NN	I-NP	O
Monday	Monday	NNP	B-NP	O
,	,	,	O	O
Wednesday	Wednesday	NNP	B-NP	O
,	,	,	O	O
and	and	CC	O	O
Friday	Friday	NNP	B-NP	O
,	,	,	O	O
Neurontin	Neurontin	NNP	B-NP	O
300	300	CD	I-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
,	,	,	O	O
which	which	WDT	B-NP	O
had	have	VBD	B-VP	O
been	be	VBN	I-VP	O
tapered	taper	VBN	I-VP	O
down	down	RB	B-ADVP	O
to	to	TO	B-PP	O
300	300	CD	B-NP	O
mg	mg	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
then	then	RB	B-ADVP	O
plan	plan	NN	B-NP	O
for	for	IN	B-PP	O
discontinuation	discontinuation	NN	B-NP	O
,	,	,	O	O
Nexium	Nexium	NN	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
Colace	Colace	NNP	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
aspirin	aspirin	NN	B-NP	O
81	81	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
amiodarone	amiodarone	NN	B-NP	O
200	200	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
q.d.	q.d.	FW	I-ADVP	O
,	,	,	O	O
Atenolol	Atenolol	NN	B-NP	O
50	50	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
q.d.	q.d.	FW	I-ADVP	O
,	,	,	O	O
Senna	Senna	NNP	B-NP	O
,	,	,	O	O
Coumadin	Coumadin	NNP	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.d.	q.d.	NN	I-NP	O
,	,	,	O	O
methadone	methadone	NN	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
pain	pain	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
regular	regular	JJ	B-NP	B-protein
insulin	insulin	NN	I-NP	I-protein
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
cefotaxime	cefotaxime	NN	B-NP	O
2	2	CD	I-NP	O
g	g	NN	I-NP	O
IV	IV	CD	B-NP	O
injections	injection	NNS	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
-LRB-	-LRB-	HYPH	B-NP	O
final	final	JJ	I-NP	O
dose	dose	NN	I-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
day	day	NN	I-NP	O
of	of	IN	B-PP	O
admission	admission	NN	B-NP	B-protein
-RRB-	-RRB-	NN	I-NP	I-protein
.	.	.	O	O

SOCIAL	SOCIAL	NNP	B-NP	O
HISTORY	HISTORY	NNP	I-NP	O
:	:	:	O	O
Resident	Resident	NNP	B-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
Mi	Mi	NNP	I-NP	O
Ville	Ville	NNP	I-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
past	past	JJ	I-NP	O
three	three	CD	I-NP	O
weeks	week	NNS	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
is	be	VBZ	B-VP	O
married	marry	VBN	I-VP	O
.	.	.	O	O

Tobacco	Tobacco	NNP	B-NP	O
history	history	NN	I-NP	O
,	,	,	O	O
one-and-a-half	one-and-a-half	JJ	B-NP	O
packs	pack	NNS	I-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
,	,	,	O	O
smoking	smoke	VBG	B-VP	O
x40	x40	CD	B-NP	O
years	year	NNS	I-NP	O
but	but	CC	O	O
has	have	VBZ	B-VP	O
quit	quit	VBN	I-VP	O
.	.	.	O	O

No	No	DT	B-NP	O
alcohol	alcohol	NN	I-NP	O
use	use	NN	I-NP	O
.	.	.	O	O

Over	Over	IN	B-PP	O
the	the	DT	B-NP	O
past	past	JJ	I-NP	O
seven	seven	CD	I-NP	O
years	year	NNS	I-NP	O
.	.	.	O	O

FAMILY	FAMILY	NN	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
Noncontributory	Noncontributory	JJ	B-ADJP	O
.	.	.	O	O

PHYSICAL	PHYSICAL	JJ	B-NP	O
EXAMINATION	EXAMINATION	NN	I-NP	O
:	:	:	O	O
Upon	Upon	IN	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
afebrile	afebrile	NN	B-NP	O
,	,	,	O	O
pulse	pulse	NN	B-NP	O
80s	80	NNS	I-NP	O
,	,	,	O	O
blood	blood	NN	B-NP	O
pressure	pressure	NN	I-NP	O
126/72	126/72	CD	I-NP	O
,	,	,	O	O
and	and	CC	O	O
oxygen	oxygen	NN	B-NP	O
saturation	saturation	NN	I-NP	O
96	96	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
2	2	CD	B-NP	O
liters	liter	NNS	I-NP	O
.	.	.	O	O

General	General	JJ	B-NP	O
appearance	appearance	NN	I-NP	O
:	:	:	O	O
Not	Not	RB	B-ADJP	O
acutely	acutely	RB	I-ADJP	O
in	in	IN	B-PP	O
distress	distress	NN	B-NP	O
,	,	,	O	O
talking	talk	VBG	B-VP	O
in	in	IN	B-PP	O
full	full	JJ	B-NP	O
sentences	sentence	NNS	I-NP	O
,	,	,	O	O
ruddy	ruddy	NN	B-NP	O
appearing	appear	VBG	B-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
face	face	NN	I-NP	O
,	,	,	O	O
but	but	CC	O	O
stable	stable	JJ	B-ADJP	O
per	per	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
.	.	.	O	O

Head	Head	NN	B-NP	O
and	and	CC	I-NP	O
neck	neck	NN	I-NP	O
exam	exam	NN	I-NP	O
revealed	reveal	VBD	B-VP	O
pupils	pupil	NNS	B-NP	O
that	that	WDT	B-NP	O
were	be	VBD	B-VP	O
equally	equally	RB	B-ADJP	O
round	round	JJ	I-ADJP	O
and	and	CC	I-ADJP	O
reactive	reactive	JJ	I-ADJP	O
to	to	TO	B-PP	O
light	light	NN	B-NP	O
.	.	.	O	O

Extraocular	Extraocular	JJ	B-NP	O
movements	movement	NNS	I-NP	O
were	be	VBD	B-VP	O
intact	intact	JJ	B-ADJP	O
.	.	.	O	O

No	No	DT	B-NP	O
sinus	sinus	NN	I-NP	O
tenderness	tenderness	NN	I-NP	O
.	.	.	O	O

JVP	JVP	NN	B-NP	B-protein
was	be	VBD	B-VP	O
around	around	IN	B-NP	O
9	9	CD	I-NP	O
cm	cm	NN	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
lymphadenopathy	lymphadenopathy	NN	I-NP	O
.	.	.	O	O

Cardiovascular	Cardiovascular	JJ	B-ADJP	O
:	:	:	O	O
Regular	Regular	JJ	B-NP	O
rate	rate	NN	I-NP	O
and	and	CC	I-NP	O
rhythm	rhythm	NN	I-NP	O
.	.	.	O	O

Normal	Normal	JJ	B-NP	O
S1	S1	NN	I-NP	B-protein
and	and	CC	O	O
S2	S2	NN	B-NP	B-protein
,	,	,	O	O
2/6	2/6	CD	B-NP	O
systolic	systolic	JJ	I-NP	O
ejection	ejection	NN	I-NP	O
murmur	murmur	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
upper	upper	JJ	I-NP	O
sternal	sternal	JJ	I-NP	O
border	border	NN	I-NP	O
.	.	.	O	O

Chest	Ch	JJS	B-NP	O
exam	exam	NN	I-NP	O
:	:	:	O	O
Bibasilar	Bibasilar	JJ	B-NP	O
crackles	crackle	NNS	I-NP	O
and	and	CC	O	O
right-sided	right-sided	JJ	B-NP	O
bronchial	bronchial	JJ	I-NP	O
breath	breath	NN	I-NP	O
sounds	sound	NNS	I-NP	O
and	and	CC	O	O
question	question	NN	B-NP	O
focal	focal	JJ	I-NP	O
wheeze	wheeze	NN	I-NP	O
.	.	.	O	O

Abdomen	Abdoman	NNS	B-NP	O
:	:	:	O	O
Soft	Soft	NNP	B-NP	O
,	,	,	O	O
nontender	nontender	JJ	B-ADJP	O
,	,	,	O	O
and	and	CC	O	O
nondistended	nondistended	JJ	B-ADJP	O
.	.	.	O	O

Bowel	Bowel	NN	B-NP	O
sounds	sound	NNS	I-NP	O
are	be	VBP	B-VP	O
present	present	JJ	B-ADJP	O
.	.	.	O	O

Extremities	Extremity	NNS	B-NP	O
:	:	:	O	O
No	No	DT	B-NP	O
edema	edema	NN	I-NP	O
.	.	.	O	O

Warm	Warm	NNP	B-NP	O
and	and	CC	O	O
well	well	RB	B-ADJP	O
perfused	perfuse	VBN	I-ADJP	O
.	.	.	O	O

LABORATORY	LABORATORY	NN	B-NP	O
DATA	DATA	NN	I-NP	O
:	:	:	O	O
Admission	Admission	NN	B-NP	O
laboratory	laboratory	NN	I-NP	O
values	value	NNS	I-NP	O
included	include	VBD	B-VP	O
a	a	DT	B-NP	O
Chem-7	Chem-7	NN	I-NP	B-protein
within	within	IN	B-PP	O
normal	normal	JJ	B-NP	O
limits	limit	NNS	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
creatinine	creatinine	NN	I-NP	O
of	of	IN	B-PP	O
0.8	0.8	CD	B-NP	O
and	and	CC	O	O
glucose	glucose	NN	B-NP	O
of	of	IN	B-PP	O
181	181	CD	B-NP	O
.	.	.	O	O

White	White	JJ	B-NP	O
blood	blood	NN	I-NP	O
cell	cell	NN	I-NP	O
count	count	NN	I-NP	O
of	of	IN	B-PP	O
9.8	9.8	CD	B-NP	O
,	,	,	O	O
hematocrit	hematocrit	NN	B-NP	O
of	of	IN	B-PP	O
33.6	33.6	CD	B-NP	O
,	,	,	O	O
and	and	CC	O	O
platelets	platelet	NNS	B-NP	B-cell_type
of	of	IN	B-PP	O
222	222	CD	B-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
differential	differential	NN	I-NP	O
of	of	IN	B-PP	O
88	88	CD	B-NP	O
%	%	NN	I-NP	O
neutrophils	neutrophil	NNS	I-NP	O
.	.	.	O	O

Liver	Liver	NN	B-NP	O
function	function	NN	I-NP	O
tests	test	NNS	I-NP	O
are	be	VBP	B-VP	O
significant	significant	JJ	B-NP	O
AST	AST	NN	I-NP	O
of	of	IN	B-PP	O
45	45	CD	B-NP	O
,	,	,	O	O
ALT	ALT	NN	B-NP	O
of	of	IN	B-PP	O
65	65	CD	B-NP	O
,	,	,	O	O
alkaline	alkaline	NN	B-NP	O
phosphatase	phosphatase	NN	I-NP	O
153	153	CD	I-NP	O
,	,	,	O	O
and	and	CC	O	O
total	total	JJ	B-NP	O
bilirubin	bilirubin	NN	I-NP	O
0.5	0.5	CD	I-NP	O
,	,	,	O	O
yet	yet	RB	B-ADVP	O
these	these	DT	B-NP	O
liver	liver	NN	I-NP	O
function	function	NN	I-NP	O
tests	test	NNS	I-NP	O
quickly	quickly	RB	B-ADVP	O
corrected	correct	VBD	B-VP	O
the	the	DT	B-NP	O
next	next	JJ	I-NP	O
morning	morning	NN	I-NP	O
of	of	IN	B-PP	O
an	an	DT	B-NP	O
AST	AST	NN	I-NP	O
of	of	IN	B-PP	O
21	21	CD	B-NP	O
,	,	,	O	O
ALT	ALT	NN	B-NP	O
of	of	IN	B-PP	O
47	47	CD	B-NP	O
,	,	,	O	O
alkaline	alkaline	NN	B-NP	O
phosphatase	phosphatase	NN	I-NP	O
123	123	CD	I-NP	O
,	,	,	O	O
total	total	JJ	B-NP	O
bilirubin	bilirubin	NN	I-NP	O
0.5	0.5	CD	I-NP	O
,	,	,	O	O
CK	CK	NN	B-NP	O
of	of	IN	B-PP	O
31	31	CD	B-NP	O
,	,	,	O	O
CK-MB	CK-MB	NN	B-NP	B-protein
of	of	IN	B-PP	O
1.7	1.7	CD	B-NP	O
,	,	,	O	O
troponin	troponin	NN	B-NP	O
of	of	IN	B-PP	O
less	less	JJR	B-NP	O
than	than	IN	B-PP	O
assay	assay	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
amylase	amylase	NN	B-NP	B-protein
of	of	IN	B-PP	O
23	23	CD	B-NP	O
.	.	.	O	O

Chest	Ch	JJS	B-NP	O
x-ray	x-ray	NN	I-NP	B-DNA
showing	show	VBG	B-VP	O
a	a	DT	B-NP	O
right	right	JJ	I-NP	O
upper	upper	JJ	I-NP	O
lobe	lobe	NN	I-NP	O
wedge-shaped	wedge-shaped	JJ	I-NP	O
infiltrate	infiltrate	NN	I-NP	O
,	,	,	O	O
mild	mild	JJ	B-NP	O
cardiomegaly	cardiomegaly	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
mild	mild	JJ	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
edema	edema	NN	I-NP	O
.	.	.	O	O

Electrocardiogram	Electrocardiogram	NN	B-NP	O
was	be	VBD	B-VP	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
an	an	DT	B-NP	O
old	old	JJ	I-NP	O
EKG	EKG	NN	I-NP	O
from	from	IN	B-PP	O
2004	2004	CD	B-NP	O
,	,	,	O	O
normal	normal	JJ	B-NP	O
sinus	sinus	NN	I-NP	O
rhythm	rhythm	NN	I-NP	O
at	at	IN	B-PP	O
82	82	CD	B-NP	O
,	,	,	O	O
now	now	RB	B-ADVP	O
with	with	IN	B-PP	O
slightly	slightly	RB	B-NP	O
increased	increase	VBN	I-NP	O
widening	widening	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
QRS	QRS	NN	I-NP	B-protein
complex	complex	NN	I-NP	I-protein
in	in	IN	B-PP	O
a	a	DT	B-NP	O
left	left	JJ	I-NP	O
bundle-branch	bundle-branch	NN	I-NP	O
block	block	NN	I-NP	O
pattern	pattern	NN	I-NP	O
,	,	,	O	O
hyperacute	hyperacute	JJ	B-NP	O
T	T	NN	I-NP	O
waves	wave	NNS	I-NP	O
in	in	IN	B-PP	O
V4	V4	NN	B-NP	O
and	and	CC	I-NP	O
V3	V3	NN	I-NP	B-protein
.	.	.	O	O

IMPRESSION	IMPRESSION	NN	B-NP	O
:	:	:	O	O
A	A	DT	B-NP	O
68-year-old	68-year-old	JJ	I-NP	O
gentleman	gentleman	NN	I-NP	O
with	with	IN	B-PP	O
multiple	multiple	JJ	B-NP	O
medical	medical	JJ	I-NP	O
problems	problem	NNS	I-NP	O
and	and	CC	O	O
bilateral	bilateral	JJ	B-NP	O
brachial	brachial	JJ	I-NP	O
plexopathy	plexopathy	NN	I-NP	O
of	of	IN	B-PP	O
unclear	unclear	JJ	B-NP	O
etiology	etiology	NN	I-NP	O
,	,	,	O	O
now	now	RB	B-ADVP	O
improving	improve	VBG	B-VP	O
,	,	,	O	O
who	who	WP	B-NP	O
presents	present	VBZ	B-VP	O
with	with	IN	B-PP	O
new	new	JJ	B-NP	O
right	right	JJ	I-NP	O
upper	upper	JJ	I-NP	O
lobe	lobe	NN	I-NP	O
infiltrate	infiltrate	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
presence	presence	NN	I-NP	O
of	of	IN	B-PP	O
having	have	VBG	B-VP	O
an	an	DT	B-NP	O
indwelling	indwell	VBG	I-NP	O
PICC	PICC	NN	I-NP	O
line	line	NN	I-NP	O
in	in	IN	B-PP	O
place	place	NN	B-NP	O
for	for	IN	B-PP	O
IV	IV	CD	B-NP	O
antibiotics	antibiotic	NNS	I-NP	O
over	over	IN	B-PP	O
the	the	DT	B-NP	O
past	past	JJ	I-NP	O
three	three	CD	I-NP	O
weeks	week	NNS	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
a	a	DT	B-NP	O
bioprosthetic	bioprosthetic	JJ	I-NP	O
valve	valve	NN	I-NP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	NNP	B-NP	O
COURSE	COURSE	NNP	I-NP	O
BY	BY	NNP	I-NP	O
SYSTEM	SYSTEM	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

Infectious	Infectious	JJ	B-NP	O
disease	disease	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
for	for	IN	B-PP	O
likely	likely	JJ	B-NP	O
hospital-acquired	hospital-acquired	JJ	I-NP	O
pneumonia	pneumonia	NN	I-NP	O
given	give	VBN	B-VP	O
his	his	PRP$	B-NP	O
long	long	JJ	I-NP	O
hospitalization	hospitalization	NN	I-NP	O
and	and	CC	I-NP	O
rehabilitation	rehabilitation	NN	I-NP	O
stays	stay	NNS	I-NP	O
recently	recently	RB	B-ADVP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
pancultured	panculture	VBN	I-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
PICC	PICC	NN	I-NP	B-cell_line
line	line	NN	I-NP	I-cell_line
was	be	VBD	B-VP	O
discontinued	discontinue	VBN	I-VP	O
and	and	CC	O	O
the	the	DT	B-NP	O
tip	tip	NN	I-NP	B-protein
was	be	VBD	B-VP	O
cultured	culture	VBN	I-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
covered	cover	VBN	I-VP	O
broadly	broadly	RB	B-ADVP	O
initially	initially	RB	I-ADVP	O
with	with	IN	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
,	,	,	O	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
ceftazidime	ceftazidime	NN	B-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
further	far	JJR	B-NP	O
review	review	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
culture	culture	NN	I-NP	O
data	datum	NNS	I-NP	O
during	during	IN	B-PP	O
the	the	DT	B-NP	O
hospital	hospital	NN	I-NP	O
course	course	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
began	begin	VBD	B-VP	O
to	to	TO	I-VP	O
grow	grow	VB	I-VP	O
coagulase-negative	coagulase-negative	JJ	B-NP	O
Staphylococcus	Staphylococcus	NNP	I-NP	O
that	that	WDT	B-NP	O
was	be	VBD	B-VP	O
resistant	resistant	JJ	B-ADJP	O
to	to	TO	B-PP	O
methicillin	methicillin	NN	B-NP	O
from	from	IN	B-PP	O
both	both	CC	O	O
the	the	DT	B-NP	O
PICC	PICC	NN	I-NP	B-cell_line
line	line	NN	I-NP	I-cell_line
culture	culture	NN	I-NP	I-cell_line
,	,	,	O	O
as	as	RB	B-ADVP	O
well	well	RB	I-ADVP	O
his	his	PRP$	B-NP	O
blood	blood	NN	I-NP	O
cultures	culture	NNS	I-NP	O
from	from	IN	B-PP	O
11/10/05	11/10/05	CD	B-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
chest	chest	NN	I-NP	O
CT	CT	NN	I-NP	O
was	be	VBD	B-VP	O
significant	significant	JJ	B-ADJP	O
for	for	IN	B-PP	O
an	an	DT	B-NP	O
extensive	extensive	JJ	I-NP	O
area	area	NN	I-NP	O
of	of	IN	B-PP	O
ground	ground	NN	B-NP	O
glass	glass	NN	I-NP	O
opacity	opacity	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
upper	upper	JJ	I-NP	O
lobe	lobe	NN	I-NP	O
with	with	IN	B-PP	O
smaller	small	JJR	B-NP	O
areas	area	NNS	I-NP	O
in	in	IN	B-PP	O
other	other	JJ	B-NP	O
lobes	lobe	NNS	I-NP	O
.	.	.	O	O

Bilateral	Bilateral	JJ	B-NP	O
mediastinal	mediastinal	JJ	I-NP	O
adenopathy	adenopathy	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
.	.	.	O	O

Infection	Infection	NN	B-NP	O
was	be	VBD	B-VP	O
thought	think	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
the	the	DT	B-NP	O
most	most	RBS	I-NP	O
likely	likely	JJ	I-NP	O
diagnosis	diagnosis	NN	I-NP	O
in	in	IN	B-PP	O
view	view	NN	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
rapidity	rapidity	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
chest	ch	JJS	I-NP	O
film	film	NN	I-NP	O
changes	change	NNS	I-NP	O
.	.	.	O	O

Other	Other	JJ	B-NP	O
possibilities	possibility	NNS	I-NP	O
included	include	VBD	B-VP	O
bronchoalveolar	bronchoalveolar	JJ	B-NP	O
cell	cell	NN	I-NP	O
carcinoma	carcinoma	NN	I-NP	O
or	or	CC	O	O
lymphoma	lymphoma	NN	B-NP	O
per	per	IN	B-PP	O
the	the	DT	B-NP	O
radiologic	radiologic	JJ	I-NP	O
read	read	NN	I-NP	O
,	,	,	O	O
but	but	CC	O	O
was	be	VBD	B-VP	O
not	not	RB	O	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
clinical	clinical	JJ	I-NP	O
presentation	presentation	NN	I-NP	O
.	.	.	O	O

Per	Per	IN	B-PP	O
infectious	infectious	JJ	B-NP	O
disease	disease	NN	I-NP	O
consultation	consultation	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
pneumonia	pneumonia	NN	I-NP	O
could	could	MD	B-VP	O
be	be	VB	I-VP	O
attributed	attribute	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
MRSE	MRSE	NN	I-NP	O
PICC	PICC	NN	I-NP	O
line	line	NN	I-NP	O
bacteremia	bacteremia	NN	I-NP	O
with	with	IN	B-PP	O
secondary	secondary	JJ	B-NP	O
seating	seating	NN	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
subsequent	subsequent	JJ	I-NP	O
transthoracic	transthoracic	JJ	I-NP	O
echocardiogram	echocardiogram	NN	I-NP	O
revealed	reveal	VBD	B-VP	O
an	an	DT	B-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
of	of	IN	B-PP	O
55	55	CD	B-NP	O
%	%	NN	I-NP	O
-60	-60	CD	B-NP	O
%	%	NN	I-NP	O
,	,	,	O	O
but	but	CC	O	O
with	with	IN	B-PP	O
abnormal	abnormal	JJ	B-NP	O
paradoxical	paradoxical	JJ	I-NP	O
motion	motion	NN	I-NP	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
his	his	PRP$	B-NP	O
postoperative	postoperative	JJ	I-NP	O
status	status	NN	I-NP	O
after	after	IN	B-PP	O
aortic	aortic	JJ	B-NP	O
valve	valve	NN	I-NP	O
replacement	replacement	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
entire	entire	JJ	I-NP	O
anterior	anterior	JJ	I-NP	O
wall	wall	NN	I-NP	O
was	be	VBD	B-VP	O
hypokinetic	hypokinetic	JJ	B-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
right	right	JJ	I-NP	O
ventricular	ventricular	JJ	I-NP	O
systolic	systolic	JJ	I-NP	O
function	function	NN	I-NP	O
appeared	appear	VBD	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
normal	normal	JJ	B-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
left	left	JJ	I-NP	O
atrial	atrial	JJ	I-NP	O
size	size	NN	I-NP	O
was	be	VBD	B-VP	O
mildly	mildly	RB	I-VP	O
dilated	dilate	VBN	I-VP	O
at	at	IN	B-PP	O
4.6	4.6	CD	B-NP	O
cm	cm	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
aortic	aortic	JJ	I-NP	O
valve	valve	NN	I-NP	O
appeared	appear	VBD	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
normal	normal	JJ	B-NP	O
functioning	functioning	NN	I-NP	O
with	with	IN	B-PP	O
trace	trace	NN	B-NP	O
aortic	aortic	JJ	I-NP	O
regurgitation	regurgitation	NN	I-NP	O
.	.	.	O	O

Other	Other	JJ	B-NP	O
valvular	valvular	JJ	I-NP	O
function	function	NN	I-NP	O
appeared	appear	VBD	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
within	within	IN	B-PP	O
normal	normal	JJ	B-NP	O
limits	limit	NNS	I-NP	O
with	with	IN	B-PP	O
exception	exception	NN	B-NP	O
of	of	IN	B-PP	O
moderate-to-severe	moderate-to-severe	JJ	B-NP	O
tricuspid	tricuspid	JJ	I-NP	O
regurgitation	regurgitation	NN	I-NP	O
and	and	CC	I-NP	O
peak	peak	NN	I-NP	O
systolic	systolic	JJ	I-NP	O
pulmonary	pulmonary	JJ	I-NP	O
artery	artery	NN	I-NP	O
pressures	pressure	NNS	I-NP	O
of	of	IN	B-PP	O
31	31	CD	B-NP	O
mmHg	mmHg	NN	I-NP	O
plus	plus	CC	O	O
right	right	JJ	B-NP	O
atrial	atrial	JJ	I-NP	O
pressure	pressure	NN	I-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
pericardial	pericardial	JJ	I-NP	O
effusion	effusion	NN	I-NP	O
was	be	VBD	B-VP	O
seen	see	VBN	I-VP	O
and	and	CC	O	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
endocarditis	endocarditis	NN	B-NP	O
was	be	VBD	B-VP	O
observed	observe	VBN	I-VP	O
.	.	.	O	O

On	On	IN	B-PP	O
follow	follow	VB	B-VP	O
up	up	RP	B-PRT	O
chest	chest	NN	B-NP	O
x-rays	x-ray	NNS	I-NP	O
throughout	throughout	IN	B-PP	O
the	the	DT	B-NP	O
hospital	hospital	NN	I-NP	O
course	course	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
infiltrate	infiltrate	NN	I-NP	O
resolved	resolve	VBN	B-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
chest	chest	NN	I-NP	O
x-ray	x-ray	NN	I-NP	O
on	on	IN	B-PP	O
5/11/05	5/11/05	CD	B-NP	O
showing	show	VBG	B-VP	O
clear	clear	JJ	B-NP	O
lungs	lung	NNS	I-NP	O
and	and	CC	O	O
only	only	RB	B-NP	O
prior	prior	JJ	I-NP	O
cardiac	cardiac	JJ	I-NP	O
surgery	surgery	NN	I-NP	O
evident	evident	JJ	B-ADJP	O
without	without	IN	B-PP	O
worsening	worsen	VBG	B-VP	O
or	or	CC	O	O
continued	continued	JJ	B-NP	O
presence	presence	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
upper	upper	JJ	I-NP	O
lobe	lobe	NN	I-NP	O
infiltrate	infiltrate	NN	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
new	new	JJ	I-NP	O
PICC	PICC	NN	I-NP	O
line	line	NN	I-NP	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
per	per	IN	B-PP	O
infectious	infectious	JJ	B-NP	O
disease	disease	NN	I-NP	O
service	service	NN	I-NP	O
recommendations	recommendation	NNS	I-NP	O
for	for	IN	B-PP	O
continued	continue	VBN	B-NP	O
intravenous	intravenous	JJ	I-NP	O
treatment	treatment	NN	I-NP	O
with	with	IN	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
for	for	IN	B-PP	O
7	7	CD	B-NP	O
to	to	TO	I-NP	O
10	10	CD	I-NP	O
days	day	NNS	I-NP	O
starting	start	VBG	B-VP	O
48	48	CD	B-NP	O
hours	hour	NNS	I-NP	O
after	after	IN	B-PP	O
the	the	DT	B-NP	O
last	last	JJ	I-NP	O
blood	blood	NN	I-NP	O
culture	culture	NN	I-NP	O
was	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
.	.	.	O	O

Therefore	Therefore	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
last	last	JJ	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
IV	IV	CD	I-NP	O
antibiotics	antibiotic	NNS	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
given	give	VBN	I-VP	O
on	on	IN	B-PP	O
2/18/05	2/18/05	CD	B-NP	O
.	.	.	O	O

To	To	TO	B-VP	O
cover	cover	VB	I-VP	O
other	other	JJ	B-NP	O
gram-negative	gram-negative	JJ	I-NP	O
sources	source	NNS	I-NP	O
for	for	IN	B-PP	O
his	his	PRP$	B-NP	O
pneumonia	pneumonia	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
Infectious	Infectious	NNP	I-NP	O
Disease	Disease	NNP	I-NP	O
Service	Service	NNP	I-NP	O
also	also	RB	B-ADVP	O
suggested	suggest	VBD	B-VP	O
continuing	continue	VBG	B-NP	O
and	and	CC	I-NP	O
ceftazidime	ceftazidime	NN	I-NP	O
treatment	treatment	NN	I-NP	O
as	as	RB	B-ADVP	O
well	well	RB	I-ADVP	O
.	.	.	O	O

Therefore	Therefore	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
discharged	discharge	VBN	I-VP	O
on	on	IN	B-PP	O
both	both	CC	O	O
intravenous	intravenous	JJ	B-NP	O
vancomycin	vancomycin	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
intravenous	intravenous	JJ	B-NP	O
ceftazidime	ceftazidime	NN	I-NP	O
treatment	treatment	NN	I-NP	O
.	.	.	O	O

Because	Because	IN	B-PP	O
of	of	IN	I-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
inability	inability	NN	I-NP	O
to	to	TO	B-VP	O
pay	pay	VB	I-VP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
visiting	visit	VBG	I-NP	O
nurses	nurse	NNS	I-NP	O
to	to	TO	B-VP	O
administer	administer	VB	I-VP	O
IV	IV	CD	B-NP	O
antibiotics	antibiotic	NNS	I-NP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
discharged	discharge	VBN	I-VP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
rehabilitation	rehabilitation	NN	I-NP	O
center	center	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Cardiovascular	Cardiovascular	NNP	B-NP	O
:	:	:	O	O
Ischemia	Ischemia	NNP	B-NP	O
:	:	:	O	O
Given	Give	VBN	B-VP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
diabetes	diabetes	NN	B-NP	O
and	and	CC	I-NP	O
shortness	shortness	NN	I-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
ruled	rule	VBN	I-VP	O
out	out	RP	B-PRT	O
for	for	IN	B-PP	O
myocardial	myocardial	JJ	B-NP	O
infarction	infarction	NN	I-NP	O
with	with	IN	B-PP	O
three	three	CD	B-NP	O
negative	negative	JJ	I-NP	B-protein
cardiac	cardiac	JJ	I-NP	I-protein
enzymes	enzyme	NNS	I-NP	I-protein
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
his	his	PRP$	B-NP	O
anti-ischemic	anti-ischemic	JJ	I-NP	B-protein
regimen	regimen	NN	I-NP	I-protein
including	include	VBG	B-PP	I-protein
aspirin	aspirin	NN	B-NP	I-protein
,	,	,	O	O
statin	statin	NN	B-NP	O
,	,	,	O	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
beta	beta	SYM	B-NP	O
blockade	blockade	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
the	the	DT	B-NP	O
future	future	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
transitioned	transitione	VBN	I-VP	O
back	back	RB	B-ADVP	O
to	to	TO	B-VP	O
once	once	VB	I-VP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
dosing	dosing	NN	I-NP	O
of	of	IN	B-PP	O
beta	beta	SYM	B-NP	O
blockade	blockade	NN	I-NP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
.	.	.	O	O

Pump	Pump	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
initially	initially	RB	B-ADVP	O
presented	present	VBD	B-VP	O
in	in	IN	B-PP	O
mild	mild	JJ	B-NP	O
volume	volume	NN	I-NP	O
overload	overload	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
maintained	maintain	VBN	I-VP	O
on	on	IN	B-PP	O
his	his	PRP$	B-NP	O
home	home	NN	I-NP	O
dosing	dosing	NN	I-NP	O
of	of	IN	B-PP	O
Lasix	Lasix	NN	B-NP	O
with	with	IN	B-PP	O
good	good	JJ	B-NP	O
volume	volume	NN	I-NP	O
response	response	NN	I-NP	O
.	.	.	O	O

By	By	IN	B-PP	O
the	the	DT	B-NP	O
end	end	NN	I-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
not	not	RB	I-VP	O
requiring	require	VBG	I-VP	O
any	any	DT	B-NP	O
oxygen	oxygen	NN	I-NP	O
supplementally	supplementally	RB	B-ADVP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
discharged	discharge	VBN	I-VP	O
with	with	IN	B-PP	O
euvolemia	euvolemia	NN	B-NP	O
.	.	.	O	O

Rhythm	Rhythm	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
initially	initially	RB	B-ADVP	O
in	in	IN	B-PP	O
normal	normal	JJ	B-NP	O
sinus	sinus	NN	I-NP	O
rhythm	rhythm	NN	I-NP	O
status	status	NN	I-NP	O
post	post	NN	I-NP	O
cardioversion	cardioversion	NN	I-NP	O
for	for	IN	B-PP	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
remained	remain	VBD	B-VP	O
on	on	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
on	on	IN	B-PP	O
telemetry	telemetry	NN	B-NP	O
given	give	VBN	B-PP	O
some	some	DT	B-NP	O
increased	increase	VBN	I-NP	O
widened	widen	VBN	I-NP	O
intervals	interval	NNS	I-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
QRS	QRS	NN	I-NP	B-protein
complexes	complex	NNS	I-NP	I-protein
.	.	.	O	O

Early	Early	RB	B-ADVP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
converted	convert	VBD	B-VP	O
back	back	RB	B-ADVP	O
to	to	TO	B-PP	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
rate	rate	NN	I-NP	O
was	be	VBD	B-VP	O
controlled	control	VBN	I-VP	O
with	with	IN	B-PP	O
beta	beta	SYM	B-NP	O
blockade	blockade	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
Sternta	Sternta	NNP	I-NP	O
Center	Center	NNP	I-NP	O
And	And	CC	O	O
was	be	VBD	B-VP	O
asked	ask	VBN	I-VP	O
to	to	TO	I-VP	O
comment	comment	VB	I-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
maintained	maintain	VBN	I-VP	O
on	on	IN	B-PP	O
both	both	CC	O	O
beta	beta	SYM	B-NP	O
blockade	blockade	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
digoxin	digoxin	NN	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
also	also	RB	B-ADVP	O
continued	continue	VBD	B-VP	O
on	on	IN	B-PP	O
anticoagulation	anticoagulation	NN	B-NP	O
with	with	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
.	.	.	O	O

Interestingly	Interestingly	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
Cardiovascular	Cardiovascular	NNP	I-NP	O
Service	Service	NNP	I-NP	O
suggested	suggest	VBD	B-VP	O
that	that	IN	B-SBAR	O
possibly	possibly	RB	B-ADVP	O
some	some	DT	B-NP	O
ground-glass	ground-glass	JJ	I-NP	O
opacities	opacity	NNS	I-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
chest	chest	NN	I-NP	O
CT	CT	NN	I-NP	O
could	could	MD	B-VP	O
be	be	VB	I-VP	O
attributed	attribute	VBN	I-VP	O
to	to	TO	B-PP	O
amiodarone	amiodarone	NN	B-NP	O
lung	lung	NN	I-NP	O
toxicity	toxicity	NN	I-NP	O
.	.	.	O	O

Because	Because	IN	B-PP	O
of	of	IN	I-PP	O
this	this	DT	B-NP	O
finding	finding	NN	I-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
recommended	recommend	VBN	I-VP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
stop	stop	VB	B-VP	O
the	the	DT	B-NP	O
amiodarone	amiodarone	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
indeed	indeed	RB	I-VP	O
discontinued	discontinue	VBN	I-VP	O
through	through	IN	B-PP	O
this	this	DT	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
should	should	MD	B-VP	O
follow	follow	VB	I-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
his	his	PRP$	B-NP	O
cardiovascular	cardiovascular	JJ	I-NP	O
group	group	NN	I-NP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
to	to	TO	B-VP	O
determine	determine	VB	I-VP	O
further	further	JJ	B-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
treatment	treatment	NN	B-NP	O
for	for	IN	B-PP	O
his	his	PRP$	B-NP	O
atrial	atrial	JJ	I-NP	O
fibrillation	fibrillation	NN	I-NP	O
.	.	.	O	O

Anticoagulation	Anticoagulation	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
continue	continue	VB	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
for	for	IN	B-PP	O
goal	goal	NN	B-NP	O
INR	INR	NN	I-NP	O
between	between	IN	B-PP	O
2	2	CD	B-NP	O
to	to	TO	B-PP	O
3	3	CD	B-NP	O
.	.	.	O	O

By	By	IN	B-PP	O
the	the	DT	B-NP	O
end	end	NN	I-NP	O
of	of	IN	B-PP	O
this	this	DT	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
INR	INR	NN	I-NP	B-protein
was	be	VBD	B-VP	O
1.7	1.7	CD	B-NP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
7	7	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.h.s.	q.h.s.	NN	I-NP	O
.	.	.	O	O

That	That	DT	B-NP	O
dose	dose	NN	I-NP	O
was	be	VBD	B-VP	O
increased	increase	VBN	I-VP	O
to	to	TO	B-PP	O
7.5	7.5	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.h.s.	q.h.s.	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
should	should	MD	B-VP	O
have	have	VB	I-VP	O
his	his	PRP$	B-NP	O
INR	INR	NN	I-NP	B-protein
checked	check	VBD	B-VP	O
within	within	IN	B-PP	O
two	two	CD	B-NP	O
days	day	NNS	I-NP	O
after	after	IN	B-PP	O
discharge	discharge	NN	B-NP	O
and	and	CC	O	O
have	have	VBP	B-VP	O
his	his	PRP$	B-NP	O
Coumadin	Coumadin	NN	I-NP	O
dose	dose	NN	I-NP	O
changed	change	VBD	B-VP	O
appropriately	appropriately	RB	B-ADVP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Neurologic	Neurologic	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
previous	previous	JJ	I-NP	O
hospitalization	hospitalization	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
bilateral	bilateral	JJ	B-NP	O
brachioplexopathy	brachioplexopathy	NN	I-NP	O
.	.	.	O	O

It	It	PRP	B-NP	O
had	have	VBD	B-VP	O
been	be	VBN	I-VP	O
attributed	attribute	VBN	I-VP	O
to	to	TO	B-PP	O
possible	possible	JJ	B-NP	O
line	line	NN	I-NP	O
infection	infection	NN	I-NP	O
given	give	VBN	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
a	a	DT	B-NP	O
tick	tick	NN	I-NP	O
bite	bite	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
empirically	empirically	RB	B-ADVP	O
with	with	IN	B-PP	O
three	three	CD	B-NP	O
weeks	week	NNS	I-NP	O
of	of	IN	B-PP	O
IV	IV	CD	B-NP	O
cefotaxime	cefotaxime	NN	I-NP	O
with	with	IN	B-PP	O
moderate	moderate	JJ	B-NP	O
improvement	improvement	NN	I-NP	O
of	of	IN	B-PP	O
motor	motor	NN	B-NP	O
function	function	NN	I-NP	O
while	while	IN	B-SBAR	O
at	at	IN	B-PP	O
rehabilitation	rehabilitation	NN	B-NP	O
.	.	.	O	O

Interestingly	Interestingly	RB	B-ADVP	O
,	,	,	O	O
upon	upon	IN	B-PP	O
further	further	JJ	B-NP	O
review	review	NN	I-NP	O
of	of	IN	B-PP	O
Lyme	Lyme	NN	B-NP	O
disease	disease	NN	I-NP	O
workup	workup	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
apparently	apparently	RB	B-ADVP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
negative	negative	JJ	I-NP	O
serology	serology	NN	I-NP	O
for	for	IN	B-PP	O
Treponema	Treponema	FW	B-NP	O
pallidum	pallidum	FW	I-NP	O
IgG	IgG	NN	I-NP	B-protein
.	.	.	O	O

Confirmatory	Confirmatory	JJ	B-NP	O
tests	test	NNS	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
included	include	VBD	B-VP	O
a	a	DT	B-NP	O
Lyme	Lyme	NN	I-NP	O
disease	disease	NN	I-NP	O
titer	titer	NN	I-NP	O
was	be	VBD	B-VP	O
still	still	RB	I-VP	O
marked	mark	VBN	I-VP	O
as	as	IN	B-PP	O
pending	pende	VBG	B-VP	O
in	in	IN	B-PP	O
our	our	PRP$	B-NP	O
computer	computer	NN	I-NP	O
system	system	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
Ardbroo	Ardbroo	NNP	I-NP	O
Worth-son	Worth-son	NNP	I-NP	O
Bu	Bu	NNP	I-NP	O
Elstownw	Elstownw	NNP	I-NP	O
.	.	.	O	O

Raph	Raph	NNP	B-NP	O
Hospitals	Hospitals	NNP	I-NP	O
.	.	.	O	O

Despite	Despite	IN	B-PP	O
multiple	multiple	JJ	B-NP	O
attempts	attempt	NNS	I-NP	O
to	to	TO	B-VP	O
try	try	VB	I-VP	O
to	to	TO	I-VP	O
contact	contact	VB	I-VP	O
the	the	DT	B-NP	O
laboratory	laboratory	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
runs	run	VBZ	B-VP	O
this	this	DT	B-NP	O
particular	particular	JJ	I-NP	O
tests	test	NNS	I-NP	O
,	,	,	O	O
we	we	PRP	B-NP	O
were	be	VBD	B-VP	O
unable	unable	JJ	B-ADJP	O
to	to	TO	B-VP	O
confirm	confirm	VB	I-VP	O
or	or	CC	I-VP	O
deny	deny	VB	I-VP	O
the	the	DT	B-NP	O
presence	presence	NN	I-NP	O
of	of	IN	B-PP	O
past	past	JJ	B-NP	O
Lyme	Lyme	NN	I-NP	O
infection	infection	NN	I-NP	O
.	.	.	O	O

Therefore	Therefore	RB	B-ADVP	O
,	,	,	O	O
at	at	IN	B-PP	O
this	this	DT	B-NP	O
time	time	NN	I-NP	O
,	,	,	O	O
we	we	PRP	B-NP	O
can	can	MD	B-VP	O
only	only	RB	I-VP	O
state	state	VB	I-VP	O
that	that	IN	B-SBAR	O
his	his	PRP$	B-NP	O
bilateral	bilateral	JJ	I-NP	O
brachioplexopathy	brachioplexopathy	NN	I-NP	O
was	be	VBD	B-VP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
an	an	DT	B-NP	O
unknown	unknown	JJ	I-NP	O
and	and	CC	I-NP	O
unclear	unclear	JJ	I-NP	O
etiology	etiology	NN	I-NP	O
.	.	.	O	O

Fortunately	Fortunately	RB	B-ADVP	O
,	,	,	O	O
with	with	IN	B-PP	O
physical	physical	JJ	B-NP	O
therapy	therapy	NN	I-NP	O
and	and	CC	B-PP	O
with	with	IN	B-PP	O
time	time	NN	B-NP	O
and	and	CC	O	O
possibly	possibly	RB	B-ADVP	O
with	with	IN	B-PP	O
infusion	infusion	NN	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
IV	IV	CD	I-NP	O
cefotaxime	cefotaxime	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
motor	motor	NN	I-NP	O
function	function	NN	I-NP	O
has	have	VBZ	B-VP	O
improved	improve	VBN	I-VP	O
.	.	.	O	O

At	At	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
this	this	DT	B-NP	O
discharge	discharge	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
overall	overall	JJ	I-NP	O
upper	upper	JJ	I-NP	O
extremity	extremity	NN	I-NP	O
motor	motor	NN	I-NP	O
strength	strength	NN	I-NP	O
was	be	VBD	B-VP	O
4	4	CD	B-NP	O
+	+	SYM	O	O
/	/	SYM	O	O
5	5	CD	B-NP	O
symmetrically	symmetrically	RB	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
should	should	MD	B-VP	O
follow	follow	VB	I-VP	O
up	up	RP	B-PRT	O
very	very	RB	B-ADVP	O
closely	closely	RB	I-ADVP	O
with	with	IN	B-PP	O
his	his	PRP$	B-NP	O
primary	primary	JJ	I-NP	O
care	care	NN	I-NP	O
physician	physician	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
his	his	PRP$	B-NP	O
neurologist	neurologist	NN	I-NP	O
in	in	IN	B-PP	O
one	one	CD	B-NP	O
month	month	NN	I-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
that	that	DT	B-NP	O
time	time	NN	I-NP	O
,	,	,	O	O
his	his	PRP$	B-NP	O
neurologist	neurologist	NN	I-NP	O
should	should	MD	B-VP	O
confirm	confirm	VB	I-VP	O
or	or	CC	I-VP	O
negate	negate	VB	I-VP	O
the	the	DT	B-NP	O
possibility	possibility	NN	I-NP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
neurologic	neurologic	JJ	I-NP	O
symptoms	symptom	NNS	I-NP	O
may	may	MD	B-VP	O
have	have	VB	I-VP	O
been	be	VBN	I-VP	O
caused	cause	VBN	I-VP	O
by	by	IN	B-PP	O
Lyme	Lyme	NN	B-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
should	should	MD	B-VP	O
continue	continue	VB	I-VP	O
physical	physical	JJ	B-NP	O
therapy	therapy	NN	I-NP	O
at	at	IN	B-PP	O
rehabilitation	rehabilitation	NN	B-NP	O
and	and	CC	B-PP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
should	should	MD	B-VP	O
continue	continue	VB	I-VP	O
his	his	PRP$	B-NP	O
Neurontin	Neurontin	NNP	I-NP	O
taper	taper	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
currently	currently	RB	B-ADVP	O
is	be	VBZ	B-VP	O
on	on	IN	B-PP	O
100	100	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
and	and	CC	O	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
tapered	taper	VBN	I-VP	O
to	to	TO	B-PP	O
nothing	nothing	NN	B-NP	O
by	by	IN	B-PP	O
the	the	DT	B-NP	O
end	end	NN	I-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
and	and	CC	I-NP	O
rehabilitation	rehabilitation	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
will	will	MD	B-VP	O
continue	continue	VB	I-VP	O
on	on	IN	B-PP	O
methadone	methadone	NN	B-NP	O
for	for	IN	B-PP	O
his	his	PRP$	B-NP	O
chronic	chronic	JJ	I-NP	O
pain	pain	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
suffers	suffer	VBZ	B-VP	O
from	from	IN	B-PP	O
significant	significant	JJ	B-NP	O
anxiety	anxiety	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
discharged	discharge	VBN	I-VP	O
on	on	IN	B-PP	O
p.r.n.	p.r.n.	NN	B-NP	O
Ativan	Ativan	NNP	I-NP	O
at	at	IN	B-PP	O
low-dose	low-dose	JJ	B-ADJP	O
,	,	,	O	O
as	as	IN	B-SBAR	O
higher	high	JJR	B-NP	O
doses	dose	NNS	I-NP	O
tend	tend	VBP	B-VP	O
to	to	TO	I-VP	O
make	make	VB	I-VP	O
him	him	PRP	B-NP	O
sleepier	sleepy	JJR	B-ADJP	O
and	and	CC	I-ADJP	O
oversedated	oversedate	VBN	I-ADJP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Endocrine	Endocrine	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
with	with	IN	B-PP	O
diabetes	diabetes	NN	B-NP	O
mellitus	mellitus	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
initially	initially	RB	I-VP	O
admitted	admit	VBN	I-VP	O
with	with	IN	B-PP	O
taking	take	VBG	B-VP	O
metformin	metformin	NN	B-NP	O
1000	1000	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.a.m.	q.a.m.	NN	I-NP	O
and	and	CC	O	O
500	500	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.h.s.	q.h.s.	NN	I-NP	O
Because	Because	IN	B-PP	O
of	of	IN	I-PP	O
his	his	PRP$	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
and	and	CC	O	O
multiple	multiple	JJ	B-NP	O
studies	study	NNS	I-NP	O
,	,	,	O	O
this	this	DT	B-NP	O
was	be	VBD	B-VP	O
discontinued	discontinue	VBN	I-VP	O
transiently	transiently	RB	B-ADVP	O
and	and	CC	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
regular	regular	JJ	I-NP	O
insulin	insulin	NN	I-NP	O
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
the	the	DT	B-NP	O
end	end	NN	I-NP	O
of	of	IN	B-PP	O
this	this	DT	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
placed	place	VBN	I-VP	O
back	back	RB	B-ADVP	O
on	on	IN	B-PP	O
those	those	DT	B-NP	O
home	home	NN	I-NP	O
doses	dose	NNS	I-NP	O
of	of	IN	B-PP	O
metformin	metformin	NN	B-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
will	will	MD	B-VP	O
continue	continue	VB	I-VP	O
his	his	PRP$	B-NP	O
ACE	ACE	NN	I-NP	O
inhibitor	inhibitor	NN	I-NP	O
for	for	IN	B-PP	O
his	his	PRP$	B-NP	O
diabetes	diabete	NNS	I-NP	O
,	,	,	O	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
for	for	IN	B-PP	O
his	his	PRP$	B-NP	O
significant	significant	JJ	I-NP	O
cardiac	cardiac	JJ	I-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Pulmonary	Pulmonary	NNP	B-NP	O
:	:	:	O	O
Much	Much	NNP	B-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
process	process	NN	I-NP	O
can	can	MD	B-VP	O
be	be	VB	I-VP	O
attributed	attribute	VBN	I-VP	O
to	to	TO	B-PP	O
his	his	PRP$	B-NP	O
pneumonia	pneumonia	NN	I-NP	O
as	as	IN	B-SBAR	O
treated	treat	VBN	B-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
statements	statement	NNS	I-NP	O
above	above	RB	B-ADVP	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
will	will	MD	B-VP	O
continue	continue	VB	I-VP	O
on	on	IN	B-PP	O
p.r.n.	p.r.n.	NN	B-NP	O
Atrovent	Atrovent	NN	I-NP	O
and	and	CC	O	O
albuterol	albuterol	NN	B-NP	O
nebulizer	nebulizer	NN	I-NP	O
treatment	treatment	NN	I-NP	O
for	for	IN	B-PP	O
possible	possible	JJ	B-NP	O
wheezing	wheezing	NN	I-NP	O
during	during	IN	B-PP	O
his	his	PRP$	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
is	be	VBZ	B-VP	O
hoped	hop	VBN	I-VP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
Ativan	Ativan	NNP	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
dosing	dosing	NN	I-NP	O
also	also	RB	B-ADVP	O
contribute	contribute	VBP	B-VP	O
to	to	TO	B-PP	O
less	less	RBR	B-NP	O
subjective	subjective	JJ	I-NP	O
shortness	shortness	NN	I-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
alleviation	alleviation	NN	B-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
anxiety	anxiety	NN	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Gastrointestinal	Gastrointestinal	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
,	,	,	O	O
periodically	periodically	RB	B-ADVP	O
,	,	,	O	O
throughout	throughout	IN	B-PP	O
his	his	PRP$	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
complained	complain	VBD	B-VP	O
of	of	IN	B-PP	O
mild	mild	JJ	B-NP	O
epigastric	epigastric	JJ	I-NP	O
pain	pain	NN	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
KUB	KUB	NN	I-NP	B-protein
showed	show	VBD	B-VP	O
no	no	DT	B-NP	O
perforation	perforation	NN	I-NP	O
and	and	CC	O	O
no	no	DT	B-NP	O
obvious	obvious	JJ	I-NP	O
obstruction	obstruction	NN	I-NP	O
,	,	,	O	O
but	but	CC	O	O
with	with	IN	B-PP	O
many	many	JJ	B-NP	O
loops	loop	NNS	I-NP	O
of	of	IN	B-PP	O
bowel	bowel	NN	B-NP	O
with	with	IN	B-PP	O
stool	stool	NN	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
bowel	bowel	NN	I-NP	O
regimen	regimen	NN	I-NP	O
including	include	VBG	B-PP	O
Colace	Colace	NN	B-NP	O
,	,	,	O	O
senna	senna	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
Dulcolax	Dulcolax	NN	B-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
By	By	IN	B-PP	O
the	the	DT	B-NP	O
end	end	NN	I-NP	O
of	of	IN	B-PP	O
this	this	DT	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
appeared	appear	VBD	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
less	less	RBR	B-ADJP	O
symptomatic	symptomatic	JJ	I-ADJP	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
will	will	MD	B-VP	O
continue	continue	VB	I-VP	O
his	his	PRP$	B-NP	O
trial	trial	NN	I-NP	O
of	of	IN	B-PP	O
simethicone	simethicone	NN	B-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
for	for	IN	B-PP	O
abdominal	abdominal	JJ	B-NP	O
gas	gas	NN	I-NP	O
and	and	CC	I-NP	O
bloating	bloating	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
will	will	MD	B-VP	O
continue	continue	VB	I-VP	O
on	on	IN	B-PP	O
his	his	PRP$	B-NP	O
proton	proton	NN	I-NP	O
pump	pump	NN	I-NP	O
inhibitor	inhibitor	NN	I-NP	O
,	,	,	O	O
Nexium	Nexium	NN	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-NP	O
q.d.	q.d.	FW	I-NP	O
CODE	CODE	NN	I-NP	O
STATUS	STATUS	NNS	I-NP	O
:	:	:	O	O
He	He	PRP	B-NP	O
remains	remain	VBZ	B-VP	O
full	full	JJ	B-NP	O
code	code	NN	I-NP	O
throughout	throughout	IN	B-PP	O
his	his	PRP$	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
.	.	.	O	O

DISPOSITION	DISPOSITION	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
discharged	discharge	VBN	I-VP	O
to	to	TO	B-PP	O
rehabilitation	rehabilitation	NN	B-NP	O
where	where	WRB	B-ADVP	O
he	he	PRP	B-NP	O
will	will	MD	B-VP	O
continue	continue	VB	I-VP	O
IV	IV	CD	B-NP	O
antibiotic	antibiotic	JJ	I-NP	O
support	support	NN	I-NP	O
for	for	IN	B-PP	O
until	until	IN	B-PP	O
2/18/05	2/18/05	CD	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
should	should	MD	B-VP	O
also	also	RB	I-VP	O
continue	continue	VB	I-VP	O
physical	physical	JJ	B-NP	O
therapy	therapy	NN	I-NP	O
for	for	IN	B-PP	O
his	his	PRP$	B-NP	O
upper	upper	JJ	I-NP	O
extremity	extremity	NN	I-NP	O
motor	motor	NN	I-NP	O
dysfunction	dysfunction	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
should	should	MD	B-VP	O
follow	follow	VB	I-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
his	his	PRP$	B-NP	O
primary	primary	JJ	I-NP	O
care	care	NN	I-NP	O
physician	physician	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
his	his	PRP$	B-NP	O
neurologist	neurologist	NN	I-NP	O
as	as	IN	B-SBAR	O
stated	state	VBN	B-VP	O
in	in	IN	B-PP	O
his	his	PRP$	B-NP	O
discharge	discharge	NN	I-NP	O
summary	summary	NN	I-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
Include	Include	VBP	B-VP	O
Tylenol	Tylenol	NN	B-NP	O
650	650	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
4h	4h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-LST	O
headache	headache	NN	B-NP	O
,	,	,	O	O
aspirin	aspirin	NN	B-NP	O
325	325	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.d.	q.d.	NN	I-NP	O
,	,	,	O	O
albuterol	albuterol	NN	B-NP	O
nebulizer	nebulizer	NN	I-NP	O
treatment	treatment	NN	I-NP	O
2.5	2.5	CD	I-NP	O
mg	mg	NN	I-NP	O
nebulizer	nebulizer	NN	I-NP	O
treatment	treatment	NN	I-NP	O
q.	q.	NN	I-NP	O
4h	4h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-NP	O
shortness	shortness	NN	I-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
or	or	CC	I-NP	O
wheeze	wheeze	NN	I-NP	O
,	,	,	O	O
Dulcolax	Dulcolax	NN	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-NP	O
q.d.	q.d.	FW	I-NP	O
p.r.n.	p.r.n.	FW	I-NP	O
constipation	constipation	NN	I-NP	O
,	,	,	O	O
ceftazidime	ceftazidime	NN	B-NP	O
1000	1000	CD	I-NP	O
mg	mg	NN	I-NP	O
IV	IV	CD	B-NP	O
q.	q.	NN	I-NP	O
8h	8h	NN	I-NP	O
.	.	.	O	O

,	,	,	O	O
to	to	TO	B-VP	O
continue	continue	VB	I-VP	O
until	until	IN	B-PP	O
1/28/05	1/28/05	CD	B-NP	O
,	,	,	O	O
digoxin	digoxin	NN	B-NP	O
0.125	0.125	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
q.d.	q.d.	FW	I-ADVP	O
,	,	,	O	O
Colace	Colace	NNP	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
Lasix	Lasix	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
q.d.	q.d.	FW	I-ADVP	O
,	,	,	O	O
Robitussin	Robitussin	NNP	B-NP	O
q.	q.	NNP	I-NP	O
4h	4h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	JJ	B-NP	O
cough	cough	NN	I-NP	O
,	,	,	O	O
Regular	Regular	JJ	B-NP	B-protein
Insulin	Insulin	NN	I-NP	I-protein
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
q.a.c.	q.a.c.	NN	I-NP	O
and	and	CC	O	O
q.h.s.	q.h.s.	NN	B-NP	O
,	,	,	O	O
lisinopril	lisinopril	NN	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
q.d.	q.d.	FW	I-ADVP	O
,	,	,	O	O
Ativan	Ativan	NNP	B-NP	O
0.25	0.25	CD	I-NP	O
mg	mg	NN	I-NP	O
to	to	TO	B-PP	O
0.5	0.5	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
8h	8h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	NN	B-NP	O
insomnia	insomnia	NN	I-NP	O
or	or	CC	I-NP	O
anxiety	anxiety	NN	I-NP	O
,	,	,	O	O
hold	hold	VBP	B-VP	O
if	if	IN	B-SBAR	O
respiration	respiration	NN	B-NP	O
rate	rate	NN	I-NP	O
is	be	VBZ	B-VP	O
less	less	JJR	B-NP	O
than	than	IN	I-NP	O
8	8	CD	I-NP	O
or	or	CC	I-NP	O
somnolent	somnolent	JJ	I-NP	O
,	,	,	O	O
methadone	methadone	NN	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
8h	8h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	JJ	B-NP	O
pain	pain	NN	I-NP	O
;	;	:	O	O
hold	hold	VBP	B-VP	O
if	if	IN	B-SBAR	O
oversedated	oversedated	JJ	B-NP	O
or	or	CC	I-NP	O
respiration	respiration	NN	I-NP	O
rate	rate	NN	I-NP	O
less	less	JJR	B-ADJP	O
than	than	IN	B-PP	O
8	8	CD	B-NP	O
,	,	,	O	O
Lopressor	Lopressor	NN	B-NP	O
50	50	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
;	;	:	O	O
hold	hold	VBP	B-VP	O
if	if	IN	B-SBAR	O
heart	heart	NN	B-NP	O
rate	rate	NN	I-NP	O
is	be	VBZ	B-VP	O
less	less	JJR	B-NP	O
than	than	IN	I-NP	O
55	55	CD	I-NP	O
or	or	CC	O	O
systolic	systolic	JJ	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
less	less	JJR	B-ADJP	O
than	than	IN	B-PP	O
100	100	CD	B-NP	O
,	,	,	O	O
senna	senna	NN	B-NP	O
two	two	CD	B-NP	O
tabs	tab	NNS	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
;	;	:	O	O
hold	hold	NN	B-NP	O
for	for	IN	B-PP	O
loose	loose	JJ	B-NP	O
stools	stool	NNS	I-NP	O
,	,	,	O	O
simethicone	simethicone	NN	B-NP	O
80	80	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-NP	O
q.i.d.	q.i.d.	FW	I-NP	O
p.r.n.	p.r.n.	FW	I-NP	O
gas	gas	NN	I-NP	O
bloating	bloating	NN	I-NP	O
or	or	CC	O	O
abdominal	abdominal	JJ	B-NP	O
discomfort	discomfort	NN	I-NP	O
,	,	,	O	O
trazodone	trazodone	NN	B-NP	O
25	25	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.h.s.	q.h.s.	FW	I-NP	O
p.r.n.	p.r.n.	FW	I-NP	O
insomnia	insomnia	NN	I-NP	O
,	,	,	O	O
vancomycin	vancomycin	NN	B-NP	O
1000	1000	CD	I-NP	O
mg	mg	NN	I-NP	O
IV	IV	CD	B-NP	O
q.	q.	NN	I-NP	O
12h.	12h.	CD	B-NP	O
;	;	:	O	O
last	last	JJ	B-NP	O
doses	dose	NNS	I-NP	O
on	on	IN	B-PP	O
1/28/05	1/28/05	CD	B-NP	O
,	,	,	O	O
Coumadin	Coumadin	NN	B-NP	O
7.5	7.5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.p.m.	q.p.m.	NN	I-NP	O
;	;	:	O	O
please	please	VB	B-VP	O
draw	draw	NN	B-NP	O
INR	INR	NN	I-NP	O
within	within	IN	B-PP	O
the	the	DT	B-NP	O
next	next	JJ	I-NP	O
one	one	CD	I-NP	O
to	to	TO	I-NP	O
two	two	CD	I-NP	O
days	day	NNS	I-NP	O
and	and	CC	O	O
dose	dose	VB	B-VP	O
the	the	DT	B-NP	O
Coumadin	Coumadin	NN	I-NP	O
appropriately	appropriately	RB	B-ADVP	O
for	for	IN	B-PP	O
INR	INR	NN	B-NP	O
goal	goal	NN	I-NP	O
2	2	CD	B-NP	O
to	to	TO	B-PP	O
3	3	CD	B-NP	O
,	,	,	O	O
simvastatin	simvastatin	NN	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
q.o.d.	q.o.d.	FW	I-ADVP	O
,	,	,	O	O
Neurontin	Neurontin	NNP	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
;	;	:	O	O
please	please	NN	B-NP	O
continue	continue	VBP	B-VP	O
to	to	TO	I-VP	O
wean	wean	VB	I-VP	O
until	until	IN	B-PP	O
completely	completely	RB	B-ADVP	O
off	off	RB	I-ADVP	O
,	,	,	O	O
Nexium	Nexium	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
q.d.	q.d.	FW	I-ADVP	O
,	,	,	O	O
Atrovent	Atrovent	JJ	B-NP	O
nebulizer	nebulizer	NN	I-NP	O
treatment	treatment	NN	I-NP	O
0.5	0.5	CD	I-NP	O
mg	mg	NN	I-NP	O
nebulizer	nebulizer	NN	I-NP	O
treatment	treatment	NN	I-NP	O
q.	q.	NN	I-NP	O
6h	6h	NN	I-NP	O
.	.	.	O	O

hour	hour	NN	B-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
shortness	shortness	NN	I-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
or	or	CC	I-NP	O
wheeze	wheeze	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
metformin	metformin	NN	B-NP	O
1000	1000	CD	I-NP	O
mg	mg	NN	I-NP	O
q.a.m.	q.a.m.	NN	I-NP	O
and	and	CC	O	O
500	500	CD	B-NP	O
mg	mg	NN	I-NP	O
q.p.m.	q.p.m.	NN	I-NP	O
eScription	eScription	NN	I-NP	O
document	document	NN	I-NP	O
:	:	:	O	O
0-8728556	0-8728556	CD	B-NP	O
EMSSten	EMSSten	NNP	I-NP	O
Tel	Tel	NNP	I-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
BEDARD	BEDARD	NNP	B-NP	O
,	,	,	O	O
RUDY	RUDY	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
CHAVIS	CHAVIS	NNP	B-NP	O
,	,	,	O	O
DOMINGO	DOMINGO	NNP	B-NP	O
Dictation	Dictation	NNP	I-NP	O
ID	ID	NNP	I-NP	O
7032931	7032931	CD	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
5/2/05	5/2/05	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
5/2/05	5/2/05	CD	B-NP	O

